The move toward targeted anti-cancer treatments has produced better outcomes with fewer side-effects for many breast cancer patients. But so far, advances in precision medicine haven’t reached people diagnosed with so-called triple-negative breast cancer. An innovative compound developed in the lab of Scripps Research chemist Matthew D. Disney, Ph.D., offers a new potential route to
Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals. Scientists found that PARP inhibitors sparked a powerful immune response when used against cancer cells with weaknesses in repairing their DNA. The study changes our understanding
Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer. Research published in the November issue of The Journal of Nuclear Medicine found that the new tracer, 99mTc-HYNIC-cMBP, produced clearer images in less time than currently used tracers and was more rapidly eliminated from the body,
Most patients diagnosed with type 2 diabetes are treated with a “one-size-fits-all” protocol that is not tailored to each person’s physiology and may leave many cases inadequately managed. A new study by scientists at the Broad Institute of MIT and Harvard and Massachusetts General Hospital (MGH) indicates that inherited genetic changes may underlie the variability
A study led by researchers at Center for Infection and Immunity (CII) at Columbia University’s Mailman School of Public Health and the Department of Medicine at the Columbia University Irving Medical Center reports on the use of a genetic sequencing method to identify viral pathogens behind unexplained respiratory illnesses in Uganda over a five-year period.
(HealthDay)—The American Medical Association has committed to working to integrate precision medicine into alternative payment models (APMs), according to an article published in the association’s AMA Wire. Implementation of the individualized approach in APMs is somewhat limited by the cost of certain precision medicine techniques. However, precision medicine, which is a tailored approach to health
If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient